M. Stauch

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial

M. Stauch, V. Heinemann, H. Hass, 2014, Journal of Cancer Research and Clinical Oncology.

Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer.

M. Stauch, Y. Ko, F. Lordick, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

A prospective, randomized trial of chemotherapy with or without the low molecular weight heparin (LMWH) enoxaparin in patients (pts) with advanced pancreatic cancer (APC): Results of the CONKO 004 trial.

M. Stauch, H. Oettle, H. Riess, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine and Carboplatin in Intensively Pretreated Patients with Metastatic Breast Cancer

A. Scharl, H. Meerpohl, F. Melchert, 2008, Oncology.

Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study.

A. Kiani, S. Al-Batran, T. Kirchner, 2017, European journal of cancer.

FOLFOXIRI Plus Cetuximab or Bevacizumab as First-Line Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer: The Randomized Phase II FIRE-4.5 (AIO KRK0116) Study

V. Heinemann, G. Prager, J. Taieb, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gemcitabine and Carboplatin in Intensively Pretreated Patients with Metastatic Breast Cancer

P. Fasching, M. Stauch, V. Heinemann, 2008, Oncology.